Intravenous Administration of High-Dose Paclitaxel Reduces Gut-Associated Lymphoid Tissue Cell Number and Respiratory Immunoglobulin A Concentrations in Mice

MoriyaTomoyuki,; FukatsuKazuhiko,; NoguchiMidori,; OkamotoKoichi,; MurakoshiSatoshi,; SaitohDaizoh,; MiyazakiMasaru,; HaseKazuo,; YamamotoJunji,

doi:10.1089/sur.2012.101

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paclitaxel: mouse models were employed in one article, with a dosage ranging from 2 to 4 mg/kg i.v. [ 206 ].…”

Section: Resultsmentioning

confidence: 99%

Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models

Huang¹,

Hwang²,

Jia³

et al. 2022

IJMS

View full text Add to dashboard Cite

Mucositis is a common and most debilitating complication associated with the cytotoxicity of chemotherapy. The condition affects the entire alimentary canal from the mouth to the anus and has a significant clinical and economic impact. Although oral and intestinal mucositis can occur concurrently in the same individual, these conditions are often studied independently using organ-specific models that do not mimic human disease. Hence, the purpose of this scoping review was to provide a comprehensive yet systematic overview of the animal models that are utilised in the study of chemotherapy-induced mucositis. A search of PubMed/MEDLINE and Scopus databases was conducted to identify all relevant studies. Multiple phases of filtering were conducted, including deduplication, title/abstract screening, full-text screening, and data extraction. Studies were reported according to the updated Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. An inter-rater reliability test was conducted using Cohen’s Kappa score. After title, abstract, and full-text screening, 251 articles met the inclusion criteria. Seven articles investigated both chemotherapy-induced intestinal and oral mucositis, 198 articles investigated chemotherapy-induced intestinal mucositis, and 46 studies investigated chemotherapy-induced oral mucositis. Among a total of 205 articles on chemotherapy-induced intestinal mucositis, 103 utilised 5-fluorouracil, 34 irinotecan, 16 platinum-based drugs, 33 methotrexate, and 32 other chemotherapeutic agents. Thirteen articles reported the use of a combination of 5-fluorouracil, irinotecan, platinum-based drugs, or methotrexate to induce intestinal mucositis. Among a total of 53 articles on chemotherapy-induced oral mucositis, 50 utilised 5-fluorouracil, 2 irinotecan, 2 methotrexate, 1 topotecan and 1 with other chemotherapeutic drugs. Three articles used a combination of these drugs to induce oral mucositis. Various animal models such as mice, rats, hamsters, piglets, rabbits, and zebrafish were used. The chemotherapeutic agents were introduced at various dosages via three routes of administration. Animals were mainly mice and rats. Unlike intestinal mucositis, most oral mucositis models combined mechanical or chemical irritation with chemotherapy. In conclusion, this extensive assessment of the literature revealed that there was a large variation among studies that reproduce oral and intestinal mucositis in animals. To assist with the design of a suitable preclinical model of chemotherapy-induced alimentary tract mucositis, animal types, routes of administration, dosages, and types of drugs were reported in this study. Further research is required to define an optimal protocol that improves the translatability of findings to humans.

show abstract

“…Paclitaxel: mouse models were employed in one article, with a dosage ranging from 2 to 4 mg/kg i.v. [ 206 ].…”

Section: Resultsmentioning

confidence: 99%

Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models

Huang¹,

Hwang²,

Jia³

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Within the HNSC microenvironment, the administration of paclitaxel via intravenous routes appears to influence mucosal immunity, potentially contributing to the development of resistance to chemotherapy. This observed effect could be linked to a plausible mechanism involving the reduction in the number of gut-associated lymphoid tissue cells 38 . This finding sheds light on the multifaceted consequences of paclitaxel administration beyond its direct cytotoxic effects, emphasizing the importance of understanding and mitigating potential immunomodulatory impacts in HNSC treatment.…”

Section: Discussionmentioning

confidence: 93%

Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment

Ding,

Lin,

Huang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

In head and neck squamous cell carcinoma (HNSC), chemoresistance is a major reason for poor prognosis. Nevertheless, there is a lack of validated biomarkers to screen for patients for categorical chemotherapy. Fc gamma binding protein (FCGBP) is a mucus protein associated with mucosal epithelial cells and has immunological functions that protect against tumors and metastasis. However, the effect of FCGBP on HNSC is unclear. In pan-cancer tissues, the expression of FCGBP and the survival status of patients were analyzed using information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Correlation analysis and Cox regression analysis were conducted to confirm the relationship and survival outcome. Bioinformatics analysis was utilized to predict the probable upstream non-coding RNA. FCGBP functioned as a potential tumor suppressor gene in HNSC. Notably, FCGBP expression was negatively correlated with enriched tumor-infiltrating macrophages and paclitaxel resistance. Cox regression with gene, clinical, and immune factors showed that FCGBP was a risk factor acting in an independent manner. In HNSC, the utmost possibly upstream non-coding RNA-related pathway of FCGBP was also discovered to be the PART1/AC007728.2/LINC00885/hsa-miR-877-5p/FCGBP axis. According to the present study, non-coding RNA-related low levels of FCGBP are a prognostic indicator and are linked to an HNSC-related immunosuppressive state.

show abstract

“…[3][4][5] Mucosal immune dysregulation can cause harmful substances, such as bacteria and antigens, to enter the body and cause diseases, including persistent stomachache, diarrhea, inflammatory bowel disease, respiratory infections, bronchitis, etc. Thus, it is extremely important to enhance mucosal immunity to prevent infection disease.…”

mentioning

confidence: 99%

DietaryApostichopus japonicusenhances the respiratory and intestinal mucosal immunity in immunosuppressive mice

Zheng

Cao

et al. 2015

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

Although Apostichopus japonicus is recognized as a food and drug resource with significant immunomodulatory activity, its role in regulating the mucosal immunity remains unclear. This study aimed to explore the effects of dietary A. japonicus on mucosal immunity with an immunosuppressive mouse model. The expression of lysozyme, secretory immunoglobulin A(sIgA), and immunoglobulin A(IgA) as well as polymeric immunoglobulin receptor(pIgR) in respiratory and intestine organs was investigated. The results showed that A. japonicus could improve both the systematic and mucosal immunity. The expression of lysozyme, sIgA, and IgA in the respiratory organ was increased more significantly. Consumption of A. japonicus with the dose of 512 mg kg−1, which equals to 1/2 sea cucumber per day for adults, showed better effects. This study elucidated positive effects of A. japonicus on mucosal immunity for the first time, suggesting that moderate consumption of A. japonicus is helpful in improving mucosal immunity and preventing exogenous infection.

show abstract

Intravenous Administration of High-Dose Paclitaxel Reduces Gut-Associated Lymphoid Tissue Cell Number and Respiratory Immunoglobulin A Concentrations in Mice

Abstract: The present data suggest high-dose PTX impairs mucosal immunity, possibly rendering patients more vulnerable to infection. Careful dose selection and new therapies may be important for maintaining mucosal immunity during PTX chemotherapy.

Cited by 4 publications

References 35 publications

Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models

Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models

Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment

DietaryApostichopus japonicusenhances the respiratory and intestinal mucosal immunity in immunosuppressive mice

Contact Info

Product

Resources

About